Related Experiment Video
Updated: Aug 15, 2026

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer
Published on: July 6, 2017
Chemoprophylaxis of colon cancer
Bandaru S Reddy1, Chinthalapally V Rao
1Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA. breddy@rci.rutgers.edu
Abstract:
There is convincing evidence that chemoprevention has the potential to be a major component of colorectal cancer control. Experimental, epidemiologic, and clinical studies provide evidence that nonsteroidal anti-inflammatory drugs (NSAIDs), particularly the selective cyclooxygenase (COX)-2 inhibitors, including celecoxib and several phytochemicals, act as anticancer agents. However, several of these chemopreventive agents induce side effects at effective high dose levels. Low doses of atorvastatin and aspirin, or atorvastatin and celecoxib, or piroxicam and difluoromethylornithine administered in combination are more effective in inhibiting chemically induced colon adenocarcinomas in male F 344 rats than are high doses of these agents given individually.
Related Concept Videos
Cancer Prevention
Some...
Drugs for Treatment of Ulcerative Colitis in IBD
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Prevention of Further Absorption of Poison

